Clinical, pathological and therapeutic aspects of oligodendroglioma

Cancer Treatment Reviews

Volumn 24, Issue 2, 1998, Pages 101-111

  Brandes, A A ^a   Fiorentino, M Y ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; LOMUSTINE; MELPHALAN; MONOCLONAL ANTIBODY KI 67; PROCARBAZINE; TENIPOSIDE; THIOTEPA; VINCRISTINE;

ARTICLE; ASTROCYTE; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER CLASSIFICATION; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE S PHASE; CHROMOSOME 19Q; COMPUTER ASSISTED TOMOGRAPHY; DRUG FATALITY; DRUG HYPERSENSITIVITY; FATIGUE; FLOW CYTOMETRY; GLIA CELL; HERPES ZOSTER; HUMAN; LETHARGY; LUNG INFECTION; MALIGNANT TRANSFORMATION; MITOSIS; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OLIGODENDROGLIOMA; PARALYTIC ILEUS; PATHOLOGY; PLOIDY; PNEUMOCYSTIS PNEUMONIA; RADIATION DOSE; RASH; SKULL RADIOGRAPHY; THROMBOCYTOPENIA;

EID: 0031663127     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90076-7     Document Type: Review

References (62)

1. Mork SJ, Lindegaard KF, Halvorsen TB. Oligodendroglioma: incidence and biological behaviour in a defined population. J Neurosurg 1985; 63: 881-889.
2. Fleury A, Menegoz F, Grosclaude P. Descriptive epidemiology of cerebral gliomas in France. Cancer 1997; 79: 1195-1202.
3. Bishop M, De la Monte SM. Dual lineage of astrocytomas. Am J Pathol 1989; 135: 517-527.
4. De la Monte SM. Uniform lineage of oligodendrogliomas. Am J Pathol 1989; 135: 529-540.
5. Linskey ME, Gilbert MR. Glial differentiation: a review with implications for new directions in neuro-oncology. Neurosurgery 1995; 36: 1-22.
6. Parker RJ, Sutton LN, Rorke LB. Oligodendroglioma of the posterior fossa in childhood. Cancer 1985; 56: 195-199.
7. Ludwig CL, Smith MT, Godfrey AD. A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 1986; 19: 15-21.
8. Chin HW, Hazel JJ, Kim TH et al. Oligodendrogliomas. A clinical study of cerebral oligodendrogliomas. Cancer 1980; 45: 1458-1499.
9. Nijjar TS, Simpson WJ, Gadalla T et al. Oligodendroglioma. The Princess Margaret Hospital experience. Cancer 1993; 71: 4402-4006.
10. Reedy DP, Bay JW, Hahn JF. Role of radiation therapy in the treatment of cerebral Oligodendroglioma: an analysis of 57 cases and a literature review. Neurosurgery 1983; 13: 499-503.
11. Shaw EG, Scheithauer WS, O'Fallon JR et al. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992; 76: 428-434.
12. Shuman WP, Griggin BR. The utility of MR in planning the radiation therapy of Oligodendroglioma. Am J Roentgenol 1987; 148: 595-600.
13. Derlon JM, Petit-Taboue MC, Chapon F. The in vivo metabolic pattern of low grade brain gliomas: a positron emission tomographic study using 18-F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery 1997; 40: 276-287.
14. Kernohan JW, Mabon RF, Svien HJ. A simplified classification of the gliomas. Proc Staff Meet Mayo Clin 1949; 24: 71-75.
15. Smith MT, Ludwig CL, Godfrey AD et al. Grading of Oligodendroglioma. Cancer 1983; 52: 2107-2114.
16. Burger PC, Rawlings CE, Cox EB. Clinicopathologic correlations in the Oligodendroglioma. Cancer 1987; 59: 1345-1352.
17. Kros JM, Troost D, Van Eden G. Oligodendroglioma. A comparison of two grading systems. Cancer 1988; 61: 2251-2259.
18. Burger PC, Scheithauer BW. Central Nervous System, Atlas of Tumor Pathology, 3rd series. Washington, DC: Armed Forces Institute of Pathology, 1994; 107-120.
19. Lindegaard KF, Mork SJ, Eide GE et al. Statistical analysis of clinicopathological feature, radiotherapy, and survival in 170 cases of Oligodendroglioma. J Neurosurg 1987; 67: 224-230.
20. Mork SJ, Halvorsen TB, Lindegaard KF. Oligodendroglioma: histological evaluation and prognosis. J Neuropathol Exp Neurol 1986; 45: 65-78.
21. Daumas-Duport C, Tucker ML, Kolles H. Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neuro-Oncol 1997; 34: 61-78.
22. Shaw EG, Scheithauer BW, O'Fallon JR. Supratentorial gliomas: a comparative study by grade and histologic type. J Neuro-Oncol 1997; 31: 273-278.
23. Wallner KE, Gonzales M, Sheline GE. The treatment of oligodendrogliomas with or without postoperative irradiation. Cancer 1988; 68: 684-688.
24. Shaw EG. In search of better prognostic indicators for patients with oligodendrogliomas. Cancer Invest 1996; 14(3): 288-289.
25. Heegard S, Sommer HM, Broholm H. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995; 76: 1809-1813.
26. Kros JM, Van Eden CG, Vissers CJ. Prognostic relevance of DNA flow cytometry in oligodendroglioma. Cancer 1992; 69: 1791-1798.
27. Kros JM, Hop WC, Godschalk JJ. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996; 78: 1107-1113.
28. Ganju V, Jenkins RB, O'Fallon JR. Prognostic factors in gliomas: a multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic and molecular markers. Cancer 1994; 74: 920-927.
29. Celli P, Nofrone I, Palma L et al. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994; 35: 1018-1034.
30. Peterson K, Cairncross JG. Oligodendroglioma. Cancer Invest 1996; 14: 243-251.
31. Kros JM, Pieterman H, Van Eden CG et al. Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 1994; 34: 959-966.
32. Sun ZM, Genka S, Shitara N et al. Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery 1988; 22: 886-891.
33. Chen R, Macdonald DR, Ramsay DA. Primary diffuse leptomeningeal oligodendroglioma. Case report. J Neurosurg 1995; 83: 724-728.
34. Macdonald DR, O'Brien RA, Gilbert JJ. Metastatic anaplastic oligodendroglioma. Neurology 1989; 39: 1593-1596.
35. Schuster H, Jellinger K, Gund A, Regele H. Extracranial metastases of anaplastic cerebral gliomas. Acta Neurochir (Wien) 1976; 35(4): 247-259.
36. Roelvink NC, Kamphorst W, Lindhout D. Concordant cerebral oligodendroglioma in identical twins. J Neurol Neurosurg Psychiatry 1986; 49: 706-708.
37. Shaw EG, Scheithauer BW, O'Fallon JR et al. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994; 34: 577-582.
38. Whitton AC, Bloom HJ. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys 1990; 18: 783-786.
39. Bullard DE, Rawlings CE, Halperin E. Oligodendroglioma, an analysis of the value of radiation therapy. Cancer 1987; 60: 2179-2188.
40. Gannett DE, Wisbeck WM, Silbegerd DL. The role of post-operative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 1994; 30: 567-573.
41. Shimizu KT, Tran LM, Mark RJ et al. Management of oligodendrogliomas. Radiology 1993; 186: 569-572.
42. Glass J, Hochberg FH, Gruber ML et al. The treatment of oligodendrogliomas and mixed oligodendrogliomaastrocytomas with PCV chemotherapy. J Neurosurg 1992; 76: 741-745.
43. Levin VA, Edwards MS, Wright DC et al. Modified pro-carbazine, CCNU and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumor. Cancer Treat Rep 1988; 64: 237-241.
44. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360-364.
45. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 1992; 31: 78-82.
46. Kyritsis AP, Yung WKA, Bruner J et al. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993; 32: 365-371.
47. Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12: 2013-2021.
48. Soffietti R, Chiò A, Mocellini C. Response of oligodendroglial tumors to PCV chemotherapy. Neurology 1994; 44: 309.
49. Glass J, Hochberg FH, Gruber ML. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytoma with PCV chemotherapy. J Neurosurg 1992; 76: 741-745.
50. Van Den Bent MJ, Kros JM, Schellens JHM. PCV-chemotherapy in anaplastic oligodendroglioma: time for a prospective, randomized study. J Neuro-Oncol 1996; 30: 130.
51. Salgado D, Costa I, Pimentel T. PCV for anaplastic oligodendroglioma. J Neuro-Oncol 1996; 30: 224.
52. Soffietti R, Rudà R, Borgognone M. Role of chemotherapy in oligodendroglial tumors: a review of the experience at the University of Toronto. J Neuro-Oncol 1996; 30: 153.
53. Duffau H, Albuquerque L, Ameri A. Chemotherapy for newly diagnosed and recurrent anaplastic oligodendrogliomas and mixed gliomas: an analysis of 42 cases. Neurology 1995; 45: 261.
54. Paleologos N, MacDonald D, Vick N. Neoadjuvant pro-carbazine, CCNU, and vincristine for anaplastic oligodendroglioma and aggressive oligodendroglioma. Neurology 1995; 45: 387.
55. Brown M, Caincross JG, Vick NA. Differential response of recurrent oligodendrogliomas versus astrocytomas to intravenous melphalan. Neurology 1990; 40: 387.
56. Soffietti R, Chiò A, Mocellini C. Treatment with carboplatinum of oligodendroglial tumors recurrent after PCV chemotherapy. Neurology 1995; 45: 261.
57. Peterson K, Paleologos N, Forsyth P. Salvage chemotherapy for oligodendroglioma. J Neurosci 1996; 85: 597-601.
58. Saarinen UM, Pihko H, Makipernaa A. High-dose thiotepa with autologus bone marrow rescue in recurrent malignant oligodendroglioma: a case report. J Neuro-Oncol 1990; 9: 57-61.
59. Mason WP, Krol GS, DeAngelis LM. Low grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46: 203-207.
60. Paleologos NA, Nicholas AV, Kachori-Evaston JP. Chemotherapy for low grade oligodendrogliomas? Ann Neurol 1994; 36: 294-295.
61. Duffey P, Chari G, Cartlidge N. Progressive deterioration of intellect and motor function occurring several decades after cranial irradiation. Arch Neurol 1996; 53: 814-818.
62. Imperato JP, Paleologos N, Vick N. Effects of treatment on long term survivors with malignant astrocytomas. Ann Neurol 1990; 28: 818-822.